Information Library
Business transformation - Cost control/reduction
To learn more about a particular aspect of Quintiles’ pharma services, biotech development or drug commercialization services, select a topic at left. If you’ve already specified a choice, you may narrow your search by selecting additional categories in any order. For example, for information on oncology drug development, start by selecting oncology. Then you can narrow your search to Central Lab, News Releases and Europe.
- Sort by: Most Recent
- Title
-
Anatomy of a Managed Partnership
May 26, 2009
Partnering affords pharma the opportunity to bolster development pipelines without taking on additional risk or adding to fixed costs. -
Jim Featherstone, Ph.D.
March 25, 2009
Jim joined Quintiles Consulting from Wood Mackenzie, a leading business intelligence and strategy consulting services company based in the UK, where he was the Global Head of Consulting for the Pharmaceuticals and Biotechnology practice. -
Matthew Eberhart
March 25, 2009
Matt is a proven business-building executive with a strong track record of implementing successful business development initiatives for consulting healthcare companies in both North America and Europe. -
Gain Capital & Retain Value
March 24, 2009
Cell Therapeutics was in need of capital to fund ongoing development expenses, but was not interested in further equity dilution. As an alternative, they considered monetizing a royalty interest in Trisenox®, their only marketed oncology product. -
Reducing Risk
August 1, 2008
A Pharma TV interview with Ben Cons -
The Next Generation of Partnerships
August 1, 2008
A Pharma TV interview with Ben Cons -
Pressures and Opportunities
August 1, 2008
A Pharma TV interview with Ben Cons
Page 1 of 1 (7 items)